Table 3.
Odds ratio (OR) and 95% confidence interval (CI) for combined immune marker (categorical variables) and B-cell lymphoma and histological subtypes.
| OR (95%CI) | p-trend | |||
|---|---|---|---|---|
| Q2 | Q3 | Q4 | ||
| BCL | ||||
| sCD23 | 1.46 (0.90–2.37) | 1.83 (1.16–2.90) | 4.85 (2.98–7.90) | < 0.0001 |
| sCD30 | 1.01 (0.64–1.59) | 0.84 (0.53–1.35) | 0.99 (0.56–1.66) | 0.72 |
| sCD27 | 1.1 (0.68–1.79) | 1.36 (0.80–2.35) | 2.35 (1.28–4.30) | 0.001 |
| CXCL13 | 1.17 (0.74–1.85) | 1.24 (0.78–1.96) | 1.96 (1.23–3.14) | 0.001 |
| CLL | ||||
| sCD23 | 1.19 (0.44–3.17) | 2.32 (0.99–5.46) | 10.3 (4.29–24.8) | < 0.0001 |
| sCD30 | 1.19 (0.48–3.0) | 0.80 (0.33–1.96) | 0.93 (0.36–2.40) | 0.67 |
| sCD27 | 0.79 (0.32–1.95) | 1.09 (0.40–2.95) | 1.68 (0.54–2.25) | 0.10 |
| CXCL13 | 0.87 (0.38–2.02) | 1.10 (0.45–2.70) | 0.80 (0.33–1.91) | 0.99 |
| FL | ||||
| sCD23 | 0.72 (0.26–1.99) | 1.53 (0.62–3.79) | 2.81 (0.90–8.75) | 0.02 |
| sCD30 | 0.81 (0.32–2.03) | 1.39 (0.50–3.88) | 1.0 (0.34–2.92) | 0.97 |
| sCD27 | 1.07 (0.34–3.36) | 0.97 (0.25–3.73) | 2.74 (0.65–11.6) | 0.08 |
| CXCL13 | 0.97 (0.39–2.45) | 0.93 (0.33–2.63) | 3.41 (1.26–9.22) | 0.01 |
| DLBCL | ||||
| sCD23 | 1.70 (0.71–4.06) | 1.19 (0.52–2.74) | 2.60 (1.04–6.48) | 0.05 |
| sCD30 | 2.33 (0.95–5.75) | 1.23 (0.49–3.07) | 2.43 (0.83–7.10) | 0.41 |
| sCD27 | 1.40 (0.57–3.41) | 1.72 (0.65–4.55) | 3.58 (1.15–11.1) | 0.08 |
| CXCL13 | 1.88 (0.78–4.55) | 1.84 (0.81–4.19) | 3.60 (1.50–8.68) | 0.01 |
B-cell lymphoma (BCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL); adjusted for BMI, education, smoking, alcohol intake, and physical activity; to see the immune marker levels associated with each quartile see Table 2. Bold: statistically significant at p-value ≤ 0.05.